- Home
- DRUG vs VNDA Comparison
DRUG vs VNDA Comparison
Compare DRUG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- VNDA
- Stock Information
- Founded
- DRUG 2019
- VNDA 2002
- Country
- DRUG United States
- VNDA United States
- Employees
- DRUG N/A
- VNDA N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- DRUG Health Care
- VNDA Health Care
- Exchange
- DRUG Nasdaq
- VNDA Nasdaq
- Market Cap
- DRUG 233.2M
- VNDA 237.9M
- IPO Year
- DRUG N/A
- VNDA 2006
- Fundamental
- Price
- DRUG $33.19
- VNDA $4.13
- Analyst Decision
- DRUG Strong Buy
- VNDA Strong Buy
- Analyst Count
- DRUG 5
- VNDA 2
- Target Price
- DRUG $83.25
- VNDA $16.50
- AVG Volume (30 Days)
- DRUG 25.6K
- VNDA 500.0K
- Earning Date
- DRUG 05-20-2025
- VNDA 05-07-2025
- Dividend Yield
- DRUG N/A
- VNDA N/A
- EPS Growth
- DRUG N/A
- VNDA N/A
- EPS
- DRUG N/A
- VNDA N/A
- Revenue
- DRUG N/A
- VNDA $201,351,000.00
- Revenue This Year
- DRUG N/A
- VNDA $14.36
- Revenue Next Year
- DRUG N/A
- VNDA $44.53
- P/E Ratio
- DRUG N/A
- VNDA N/A
- Revenue Growth
- DRUG N/A
- VNDA 13.37
- 52 Week Low
- DRUG $0.93
- VNDA $3.85
- 52 Week High
- DRUG $79.02
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- DRUG 51.77
- VNDA 37.18
- Support Level
- DRUG $29.59
- VNDA $4.20
- Resistance Level
- DRUG $32.75
- VNDA $4.51
- Average True Range (ATR)
- DRUG 1.99
- VNDA 0.16
- MACD
- DRUG 0.14
- VNDA -0.01
- Stochastic Oscillator
- DRUG 54.42
- VNDA 1.82
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.